Cardurion Pharmaceuticals

Cardurion Pharmaceuticals is a clinical-stage biotechnology company founded in 2017, focused on developing innovative therapeutics for heart failure and other cardiovascular diseases.

The company is advancing two key clinical programs: CRD-750, a PDE9 inhibitor targeting heart failure, and CRD-4730, the first CaMKII inhibitor aimed at multiple cardiovascular indications. Both candidates are currently in Phase 2 clinical trials. Headquartered in Burlington, Massachusetts, Cardurion operates a preclinical drug discovery unit in Shonan, Japan. The company was established by physician-scientist Michael E. Mendelsohn and a team of experts in cardiovascular signaling pathways. Cardurion is privately held and has received significant investments, including $300 million from Bain Capital Life Sciences and $260 million in a Series B funding round led by Ascenta Capital. The company is dedicated to transforming cardiovascular disease treatment through deep scientific research and innovation.